EXEM FOAM KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EXEM FOAM KIT (EXEM FOAM KIT).
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
| Metabolism | Diclofenac is primarily metabolized in the liver via cytochrome P450 enzymes, mainly CYP2C9, with minor contributions from CYP3A4. It undergoes hydroxylation and conjugation to form inactive metabolites. |
| Excretion | Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1–2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Bioavailability is negligible after topical application due to low systemic absorption; <5% of topically applied dose enters systemic circulation. |
| Onset of Action | Topical: Onset of relief from itching or irritation typically occurs within 30 minutes to 1 hour. |
| Duration of Action | Duration of clinical effect for topical application is typically 4–6 hours; may require reapplication. |
| Molecular Weight | 308 |
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
| Dosage form | FOAM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose to 25 mg orally once daily; for mild impairment (Child-Pugh class A), no adjustment. |
| Pediatric use | Safety and effectiveness have not been established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; however, monitor renal function as elderly patients may have decreased renal function. |
| 1st trimester | Insufficient data; avoid use unless benefit outweighs risk. |
| 2nd trimester | Insufficient data; avoid use unless benefit outweighs risk. |
| 3rd trimester | Insufficient data; avoid use unless benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for EXEM FOAM KIT (EXEM FOAM KIT).
| Placental transfer | Unknown; molecular weight suggests possible transfer. |
| Breastfeeding | No data on excretion in breast milk; caution advised. |
| Lactation Rating | L3 (Moderately Safe) - no adequate studies. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. EXEM FOAM KIT is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to any componentOpen wounds or infected skin areas
| Precautions | Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events., Gastrointestinal risk: NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal., Hepatic effects: Elevations of liver enzymes may occur; monitor liver function., Renal effects: NSAIDs can cause renal toxicity; use with caution in patients with renal impairment., Skin reactions: Serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis can occur., Anaphylactoid reactions: May occur in patients without prior exposure to diclofenac. |
| Food/Dietary |
Loading safety data…
| Teratogenic Risk | No teratogenic effects in animal studies; insufficient human data; FDA pregnancy category not assigned; avoid first trimester if possible. |
| Fetal Monitoring | Monitor maternal vital signs; fetal heart rate during prolonged use near term. |
| Fertility Effects | No known adverse effects on fertility in animals; no human data. |
| No known food interactions. Avoid excessive alcohol consumption as it may exacerbate psoriasis. |
| Clinical Pearls | Exem Foam Kit (clobetasol propionate 0.05%) is indicated for plaque psoriasis. Apply sparingly to affected areas twice daily; use for no more than 2 consecutive weeks. Limit total dosage to 50 g/week. Caution in sensitive areas (face, groin, axillae) due to increased risk of atrophy. Monitor for hypothalamic-pituitary-adrenal axis suppression when used on large surface areas or under occlusion. |
| Patient Advice | Apply a thin layer of foam only to psoriasis plaques, not normal skin. · Do not use for more than 2 weeks unless directed by your doctor. · Avoid contact with eyes, mouth, or broken skin. · Do not cover the treated area with bandages or wraps unless instructed. · Wash hands after application unless treating hands. · Inform your doctor if you have skin infections or are pregnant/breastfeeding. · Store at room temperature; do not refrigerate or expose to heat or flame. |